Research To Practice | Oncology Videos

Latest Episodes:

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Jennifer R Brown MD, PhD May 24, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 2: Emerging BTK Inhibitor-Based Combination Approaches in CLL — Jennifer R Brown MD, PhD

CME information and select publications

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Wojciech Jurczak MD, PhD May 24, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 1: Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Newly Diagnosed and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) — Wojciech Jurczak MD, PhD

CME information and select publications

Ovarian Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer May 21, 2026

Show notes

Proceedings from a live event on April 12, 2026, held during the SGO 2026 Annual Meeting on Women's Cancer and moderated by Dr Shannon Westin, including the following topics:

Introduction (0:00)
Current Role of PARP Inhibitors for Advanced Ovarian Cancer — Prof Colombo (1:59)
Strategies Targeting Folate Receptor Alpha for Advanced Ovarian Cancer — Dr Westin (25:53)
Other Novel Agents and Strategies for Advanced Ovarian Cancer — Dr Olawaiye (46:40)
Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced Ovarian Cancer — Dr Konecny (1:19:11)

CME information and select publications

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium May 20, 2026

Show notes

Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics:

Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00)
Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06)
Younger patient with metastatic PD-L1-positive gastric cancer (5:29)

CME information and select publications

PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida May 16, 2026

Show notes

Featuring an interview with Dr Wassim Abida, including the following topics:

Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00)
Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37)
Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33)
Key considerations surrounding toxicities associated with PARP inhibitors (15:25)
Potential role of saruparib; evolving nomenclature in prostate cancer (22:36)
Approach to newly diagnosed metastatic prostate cancer (26:16)
Clinical relevance of PSMA-targeted PET imaging results (29:49)
Case: A man in his mid 70s with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration receives olaparib/abiraterone/prednisone upon relapse (32:15)
Combining PARP inhibitors with other DNA repair inhibitors; insights on the PSMAddition trial (37:14)
Case: A man in his mid 60s with metastatic prostate adenocarcinoma and a BRCA germline mutation receives niraparib/abiraterone/prednisone (43:17)
Case: A man in his early 60s with mCRPC and CDK12 mutations receives talazoparib/enzalutamide (45:54)

CME information and select publications

PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida (Companion Faculty Lecture) May 16, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics:

Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00)
Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01)
Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03)
Key findings from the Phase III MAGNITUDE and TALAPRO-2 studies (15:10)
Summary of efficacy data with PARP inhibitors; toxicities (20:01)
Key findings and conclusions from the Phase III AMPLITUDE study; future directions with PARP inhibitors (23:33)

CME information and select publications

Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer May 14, 2026

Show notes

Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics:

Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00)
Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (25:18)
Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy in Advanced EC — Dr Salani (59:02)

CME information and select publications

Oncology Nursing Update: Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani May 07, 2026

Show notes

Featuring an interview with Dr Nikhil I Khushalani, including the following topics:

Overview of nonmelanoma skin cancers (0:00)
Systemic therapy for nonmelanoma skin cancers (12:11)
Immune checkpoint inhibitors for special patient populations (20:30)
Hedgehog inhibitors for basal cell carcinoma (32:14)
New developments in therapy for nonmelanoma skin cancers (38:52)
Case: A man in his early 70s with cutaneous squamous cell carcinoma receives cemiplimab (43:41)
Case: A man in his mid 70s with a history of basal cell carcinoma presents with disease of the ocular surface and receives immunotherapy (51:50)
Case: A man in his early 70s with recurrent metastatic basal cell carcinoma receives vismodegib followed by cemiplimab on disease progression (57:22)

NCPD information and select publications

Localized Colorectal Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium May 02, 2026

Show notes

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00)
Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58)
Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant treatment (13:35)

CME information and select publications

Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH Apr 30, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH

CME information and select publications